NZ740555B2 - Fusion protein - Google Patents
Fusion proteinInfo
- Publication number
- NZ740555B2 NZ740555B2 NZ740555A NZ74055516A NZ740555B2 NZ 740555 B2 NZ740555 B2 NZ 740555B2 NZ 740555 A NZ740555 A NZ 740555A NZ 74055516 A NZ74055516 A NZ 74055516A NZ 740555 B2 NZ740555 B2 NZ 740555B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- amino acid
- use according
- hepatitis
- fusion protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
The present invention relates to a fusion protein for use in the treatment and/or prevention of a hepatitis B virus infection comprising at least one hepatitis B PreS polypeptide or fragment thereof fused to at least one peptide consisting of an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 4.
Claims (9)
1. Use of a fusion protein in the manufacture of a medicament for the treatment and/or prevention of a hepatitis B virus infection, wherein the fusion protein comprises a hepatitis B PreS polypeptide fused to a peptide consisting of an amino acid SEQ ID No. 1, a peptide consisting of amino acid sequence SEQ ID No. 2, a peptide consisting of amino acid SEQ ID No. 3 and a peptide consisting of amino acid SEQ ID No. 4.
2. The use according to claim 1, wherein the amino acid sequence of the PreS polypeptide consists of SEQ ID No. 5.
3. The use according to claim 1 or claim 2, wherein the peptides consisting of amino acid sequences SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 4 are fused to the N- and/or C-terminus of the PreS polypeptide.
4. The use according to any one of claims 1 to 3, wherein the fusion protein consists of amino acid sequence SEQ ID No. 6.
5. The use according to any one of claims 1 to 4, wherein the hepatitis B virus infection is caused by a hepatitis B virus genotype A, B, C, D, E, F, G, H or a subtype thereof.
6. The use according to any one of claims 1 to 5, wherein the medicament is to be administered to an individual at least once in an amount of 0.01 µg/kg body weight to 5 mg/kg body weight.
7. The use according to claim 6, wherein the medicament is to be administered to an individual at least once in an amount of 0.1 µg/kg body weight to 2 mg/kg body weight.
8. The use according to any one of claims 1 to 7, wherein the medicament is to be administered together with at least one adjuvant and/or pharmaceutical acceptable excipient.
9. The use of any one of claims 1 to 8 substantially as herein described and with reference to any example thereof and with or without reference to the figures. i-r jlj ft o D P ?:.C d t'vj fli ni Ol in Ui \u t-
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15183983.4A EP3138579A1 (en) | 2015-09-05 | 2015-09-05 | Fusion protein for use in the treatment of a hepatitis b virus infection |
| PCT/EP2016/070824 WO2017037280A1 (en) | 2015-09-05 | 2016-09-05 | Fusion protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ740555A NZ740555A (en) | 2025-05-02 |
| NZ740555B2 true NZ740555B2 (en) | 2025-08-05 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240287144A1 (en) | Self-assembling insect ferritin nanoparticles | |
| EP3308798A3 (en) | Polypeptides and antibodies for treating hbv infection and related diseases | |
| CA2952351C (en) | Influenza virus vaccines and uses thereof | |
| EA202090738A1 (en) | METHOD FOR SAFE INDUCING IMMUNITY AGAINST RSV | |
| HRP20160798T1 (en) | RECOMBINANT ANTIGENS FROM RSV | |
| IL262805B2 (en) | CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death | |
| EA201990885A1 (en) | COMPOSITIONS CONTAINING SHORT PEPTIDES OBTAINED FROM PEDF AND THEIR APPLICATION | |
| JP2012115277A5 (en) | ||
| PE20190733A1 (en) | ANTIBODIES AGAINST DENGUE VIRUS, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS, AND METHODS OF USE | |
| RU2009119597A (en) | NEW H5 PROTEINS CODING THEIR NUCLEIC ACID MOLECULES AND VECTORS, AND THEIR APPLICATION IN MEDICINE | |
| RU2015140603A (en) | INFLUENZA VIRUS NUCLEOPROTEIN VACCINES | |
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| JP2016520534A5 (en) | ||
| RU2018112060A (en) | Fused Protein | |
| RU2019113989A (en) | MEDICINE | |
| JP2020515283A5 (en) | ||
| JP2019534242A5 (en) | ||
| WO2012162637A3 (en) | Vaccine adjuvants from self-assembling peptides | |
| NZ740555B2 (en) | Fusion protein | |
| JP2019506840A5 (en) | ||
| AR065688A1 (en) | CONJUGATES OF ANTIFUSOGENIC PEPTIDES | |
| AU2017350304B2 (en) | Influenza virus neutralizing compounds | |
| MX2013007007A (en) | Vaccines based on peptides of the complement protein c5a. | |
| MX2020001055A (en) | Malaria vaccine. | |
| JP2017500030A5 (en) |